CLSA Events, Events, Home Events

Bristol-Myers Squibb Partnering Day

bms301

Register Today
NETWORKING COCKTAIL RECEPTIONMorning pLENARY SESSIONafternoon plenary session
 Partnering Day Applications
Are Now Closed

Bristol-Myers Squibb is a leading global BioPharma company. Our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We have combined the passion and entrepreneurial spirit of a leading-edge biotech company with the experience and capabilities of a major pharmaceutical company. One of the ways we are doing this is through innovative partnerships with external companies to develop innovative medicines.

For decades, partnering has been an important element of our business strategy and as such partnering is in the DNA of Bristol-Myers Squibb having established a collaborative culture, leading alliance management capabilities and successfully built multiple blockbuster franchises and consistently realized more than half our global sales from partnered or in-licensed products. Our Business Development team works closely with R&D and commercial leadership to identify external opportunities which fit our strategy to provide transformational medicines in areas with high unmet medical need. We actively seek innovative drug programs, especially with biomarker for companion diagnostics for patient stratification, which complement our internal R&D efforts from discovery to late stage clinical trials and commercialization in following therapeutic areas:

  • Oncology – Novel immune checkpoint inhibitors and co-stimulatory agents, tumor intrinsic targets with demonstrated impact on anti-tumor immunity and the tumor microenvironment, synergy with immune checkpoint inhibitors, established non-immunosuppressive mechanisms of action, new approaches to validated cancer pathways, emerging areas of cancer biology and antibody drug conjugates (novel targets) and late preclinical / clinical-stage programs in areas of unmet medical need.
  • Cardiovascular – Heart Failure, cardiomyopathy, highly validated targets addressing CV risk with clear specialty medicine development path
  • Immunoscience – Rheumatoid arthritis, Inflammatory Bowel Disease, Lupus
  • Fibrosis – Idiopathic Pulmonary Fibrosis, Liver fibrosis (NASH), Systemic sclerosis, IgA Neuropathy
  • Genetically Defined/Rare Diseases – Focus in monogenic diseases and genetically defined therapeutics in neuromuscular (Duchenne’s and other muscular dystrophies), neurological diseases (tauopathies, synucleopathies, Nav1.7 small fiber neuropathies, other) and cardiomyopathies. Interested in novel approaches for AAV delivery and other molecular delivery systems targeting tissues such as muscle, heart, brain.
  • Technologies – Pathway analysis & novel target identification, Gene editing & bioinformatics tools, In vitro and in vivo disease models, Transgenic animals, High throughput label free platforms, Novel chemistry, compound libraries & platforms, Antibody discovery and screening,Protein and antibody engineering, Small molecules and linkers for antibodydrug conjugates (ADCs), Microfluidic systems & cellular models predicting ADME, Subcutaneous Depot Controlled Release Delivery, Drug Delivery of Highly Concentrated Injectables, Oral Delivery of Macrocyclic Peptides, Clinical biomarkers, Toxicogenomics– expression levels in cells/tissue, high throughput single cell capture and characterization, tumor specific antibody binding, Pharmacodiagnostics and imaging technologies for Bristol-Myers Squibb products

Additional information can be found on the BMS Partnering web site: http://bms.com/partnering/Pages/home.aspx 

When requesting a meeting, please describe what you would like to discuss with Bristol-Myers Squibb. Please include information about your company (services offered, technology, geographic reach, etc).

We are looking forward to meeting you.

Confirmed BMS Participants:

  • Carl Decicco, SVP Discovery
  • John Houston, SVP Disease Sciences and Biologics
  • Michael Burgess, SVP Head Exploratory Clinical and Translational Research
  • Michael Giordano, SVP Head Oncology Development
  • Douglas Manion, SVP Head Specialty Development
  • Nils Lonberg, SVP Head Oncology Biology Discovery and BDC
  • Alan Korman, VP Discovery Immuno-Oncology
  • Paul Biondi, SVP Business Development

What:

Bristol-Myers Squibb Partnering Day

When:

Monday March 21, 2016

Networking Cocktail Reception
4:30pm — 6:30pm
This event, part of the CLSA Partnering Day, will provide a great opportunity to network with BMS Senior R&D and Business Development Leadership.

Tuesday, March 22, 2016

Partner of Choice Plenary (AM Session)
8:30am – 9:00am
Join us for a morning plenary and learn how a large biopharmaceutical company evaluates external research and approaches licensing and partnerships. Registration will open at 8:00am and presentation will start promptly at 8:30am.

One-on-One Private Meetings
9:00am – 12:00pm
Application Required. Accepted applications will be given a private 45 minute one-on-one meeting with a representative from BMS.

Partner of Choice Plenary (PM Session)
1:00pm – 1:30pm
Join us for an afternoon plenary and learn how a large biopharmaceutical company evaluates external research and approaches licensing and partnerships. Registration will open at 12:30pm and presentation will start promptly at 1:00pm.

 One-on-One Private Meetings
1:30pm – 5:00pm
Application Required. Accepted applications will be given a private 45 minute one-on-one meeting with a representative from BMS.

Where:

Location:
Sofitel
223 Twin Dolphin Drive
Redwood City, CA 94065

Map

Cost:

Complimentary

Admission:

One-on-One Meeting: Application is required for one-on-one meetings. Only companies reviewed and approved will be scheduled for a one-on-one partnering meeting. Application review is on a rolling basis, so we suggest applying early due to a limited number of available appointments.

Networking Cocktail Reception: Due to high demand the reception is limited to employees of bioscience companies only. For questions please email registration@califesciences.org.

Plenary & Panel Discussion: Due to high demand the plenary is limited to employees of bioscience companies only. For questions please email registration@califesciences.org.

Attire:Business attire suggested
  • Early registration is highly advised as space is limited and there will be no on-site registration
  • Pre-registered attendees will receive an immediate receipt/confirmation after submission
  • Please print this receipt/confirmation and bring it with you to receive your conference credentials
  • Photo ID (driver’s license or passport) will be required at check-in
  • All sales are final

Please mail your event-related questions to: registration@califesciences.org or you can contact us via phone: 650-871-3257.

Is your company a member? Click here to check.